BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luo W, Yang G, Qiu J, Luan J, Zhang Y, You L, Feng M, Zhao F, Liu Y, Cao Z, Zheng L, Zhang T, Zhao Y. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? Cancer Med 2019;8:6403-13. [PMID: 31475468 DOI: 10.1002/cam4.2384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Madamsetty VS, Pal K, Dutta SK, Wang E, Mukhopadhyay D. Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer. Cancers (Basel) 2020;12:E1189. [PMID: 32397114 DOI: 10.3390/cancers12051189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ricciardiello F, Gang Y, Palorini R, Li Q, Giampà M, Zhao F, You L, La Ferla B, De Vitto H, Guan W, Gu J, Zhang T, Zhao Y, Chiaradonna F. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. Oncogene 2020;39:4103-17. [PMID: 32235891 DOI: 10.1038/s41388-020-1260-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
3 Luo W, Zheng L, Zhang T. Do novel treatment strategies enhance T cell-mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapy. Int Immunopharmacol 2021;90:107199. [PMID: 33246828 DOI: 10.1016/j.intimp.2020.107199] [Reference Citation Analysis]
4 Bleker de Oliveira M, Koshkin V, Liu G, Krylov SN. Analytical Challenges in Development of Chemoresistance Predictors for Precision Oncology. Anal Chem 2020;92:12101-10. [PMID: 32790291 DOI: 10.1021/acs.analchem.0c02644] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Fu Y, Ricciardiello F, Yang G, Qiu J, Huang H, Xiao J, Cao Z, Zhao F, Liu Y, Luo W, Chen G, You L, Chiaradonna F, Zheng L, Zhang T. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. Cells 2021;10:497. [PMID: 33669111 DOI: 10.3390/cells10030497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Luo W, Yang G, Qiu J, Luan J, Zhang Y, You L, Feng M, Zhao F, Liu Y, Cao Z, Zheng L, Zhang T, Zhao Y. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? Cancer Med 2019;8:6403-13. [PMID: 31475468 DOI: 10.1002/cam4.2384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
7 Masetto F, Chegaev K, Gazzano E, Mullappilly N, Rolando B, Arpicco S, Fruttero R, Riganti C, Donadelli M. MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells. Biochim Biophys Acta Mol Cell Res 2020;1867:118824. [PMID: 32828758 DOI: 10.1016/j.bbamcr.2020.118824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Qiu F, Chen J, Cao J, Diao F, Huang P. Low‑intensity low‑frequency ultrasound enhances the chemosensitivity of gemcitabine‑resistant ASPC‑1 cells via PI3K/AKT/NF‑κB pathway‑mediated ABC transporters. Oncol Rep 2020;44:1158-68. [PMID: 32705228 DOI: 10.3892/or.2020.7671] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Cordani M, Resines-Urien E, Gamonal A, Milán-Rois P, Salmon L, Bousseksou A, Costa JS, Somoza Á. Water Soluble Iron-Based Coordination Trimers as Synergistic Adjuvants for Pancreatic Cancer. Antioxidants (Basel) 2021;10:66. [PMID: 33430324 DOI: 10.3390/antiox10010066] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 García-Costela M, Escudero-Feliú J, Puentes-Pardo JD, San Juán SM, Morales-Santana S, Ríos-Arrabal S, Carazo Á, León J. Circadian Genes as Therapeutic Targets in Pancreatic Cancer. Front Endocrinol (Lausanne) 2020;11:638. [PMID: 33042011 DOI: 10.3389/fendo.2020.00638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sim W, Lim WM, Hii LW, Leong CO, Mai CW. Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases. World J Gastroenterol 2022; 28(18): 1934-1945 [DOI: 10.3748/wjg.v28.i18.1934] [Reference Citation Analysis]
12 Li H, Chen M, Yang Z, Wang Q, Wang J, Jin D, Yang X, Chen F, Zhou X, Luo K. Phillygenin, a MELK Inhibitor, Inhibits Cell Survival and Epithelial-Mesenchymal Transition in Pancreatic Cancer Cells. Onco Targets Ther 2020;13:2833-42. [PMID: 32308417 DOI: 10.2147/OTT.S238958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]